ProPhase Labs shares surge 20.15% premarket after securing USPTO approval for esophageal adenocarcinoma risk assessment patent.

ProPhase Labs (NASDAQ:PRPH) surged 20.15% in premarket trading, driven by the announcement on August 12, 2025, that the U.S. Patent and Trademark Office (USPTO) granted full approval for its U.S. Patent protecting the BE-Smart™ test for esophageal adenocarcinoma risk assessment. This intellectual property milestone strengthens the company’s diagnostic platform exclusivity, signaling potential revenue growth and market differentiation. The patent approval followed earlier positive developments, including a $3 million convertible notes financing in July and a successful clinical study validating the test’s performance in June. While other news, such as Nasdaq compliance updates and earnings calls, occurred in the period, the patent approval was the most directly impactful, aligning with the stock’s sharp premarket rise.